| Dr Tyler Heuer, OD | |
|
310 8th Ave Nw Ste 507, Aberdeen, SD 57401-2369 | |
| (605) 520-3927 | |
| Not Available |
| Full Name | Dr Tyler Heuer |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 11 Years |
| Location | 310 8th Ave Nw Ste 507, Aberdeen, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588999668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 762 (South Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ophthalmology Associates 010196 | 4284616657 | 3 |
News Archive
Lifestyle changes could reduce the risk for rheumatoid arthritis in patients predisposed to the condition, Dutch researchers suggest.
Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Blue Cross Blue Shield of Massachusetts, a locally-based, community-focused health plan, today announced its goals for advancing the company's four community focus areas - developed to support those living and working in Massachusetts.
XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.
› Verified 9 days ago
| Provider Name | Ophthalmology Associates 010196 |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1306900634 PECOS PAC ID: 4284616657 Enrollment ID: O20040601001348 |
News Archive
Lifestyle changes could reduce the risk for rheumatoid arthritis in patients predisposed to the condition, Dutch researchers suggest.
Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Blue Cross Blue Shield of Massachusetts, a locally-based, community-focused health plan, today announced its goals for advancing the company's four community focus areas - developed to support those living and working in Massachusetts.
XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tyler Heuer, OD 310 8th Ave Nw Ste 507, Aberdeen, SD 57401-2369 Ph: (605) 520-3927 | Dr Tyler Heuer, OD 310 8th Ave Nw Ste 507, Aberdeen, SD 57401-2369 Ph: (605) 520-3927 |
News Archive
Lifestyle changes could reduce the risk for rheumatoid arthritis in patients predisposed to the condition, Dutch researchers suggest.
Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Blue Cross Blue Shield of Massachusetts, a locally-based, community-focused health plan, today announced its goals for advancing the company's four community focus areas - developed to support those living and working in Massachusetts.
XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.
› Verified 9 days ago
Kara M Lunzman, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 508 Moccasin Dr, Aberdeen, SD 57401 Phone: 605-225-4046 Fax: 605-225-9728 | |
Vision Care Associates, Llp Optometrist Medicare: Medicare Enrolled Practice Location: 310 8th Ave Nw, Aberdeen, SD 57401 Phone: 605-225-2020 Fax: 605-226-2614 | |
Darren Dohman, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 310 8th Ave Nw Ste 503, Aberdeen, SD 57401 Phone: 605-225-2020 | |
Marshall Dorsett, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 310 8th Ave Nw Ste 503, Aberdeen, SD 57401 Phone: 605-225-2020 | |
Sara Serfoss, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 310 8th Ave Nw Ste 503, Aberdeen, SD 57401 Phone: 605-225-2020 Fax: 605-725-2614 | |
James Olson, OD Optometrist Medicare: Medicare Enrolled Practice Location: 310 8th Ave Nw Ste 503, Aberdeen, SD 57401 Phone: 605-225-2020 | |
Robert W Dohman, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3820 7th Ave Se, Aberdeen, SD 57401 Phone: 605-725-5110 Fax: 605-725-5111 |